SV Health Investors

Avitide, Inc. discovers, manufactures, and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry. It offers affinity separation technology that enables customers to achieve bioprocess development timelines, reduce program risk, predict commercial scalability, and reduce manufacturing costs. The company also develops affinity purification solutions for the manufacturing of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Avitide, Inc. was incorporated in 2012 and is based in Lebanon, New Hampshire.

Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

CardioKinetix, Inc. develops transcatheter implants. Its portfolio includes Parachute, a ventricular partitioning device that intends to treat heart failure resulting from a heart attack in patients by improving the overall cardiac function. The company’s Parachute is deployed within the left ventricle for patients who have developed ischemic left sided heart failure following a heart attack. It serves customers primarily in the United States, France, Germany, Latvia, Portugal, Serbia, Slovenia, the Netherlands, and the United Kingdom. The company was incorporated in 2002 and is headquartered in Menlo Park, California.

VHsquared Ltd. develops oral biologics for immuno-inflammatory targets in the gastro intestinal tract. The company identifies, screens, selects, and engineers Vorabodies, a transformational therapy for the treatment of inflammatory bowel disease. It uses its Vorabody platform to generate potent protease resistant domain antibodies for oral administration. The company was incorporated in 2010 and is based in Cambridge, United Kingdom.

LeukoSite develops small molecule and monoclonal antibody treatment and care for inflammatory, autoimmune, cancer applications, and viral diseases. Its product portfolio includes CAMPATH, a treatment intended for the cure of chronic lymphocytic leukemia, LDP-977 for the treatment of bronchial asthma, LDP-02 for inflammatory bowel disease, and more. LeukoSite also had nine partner-funded research and discovery programs.

NovaLign Orthopaedics formerly known as OsteoLign is an orthopaedic medical device company based in Memphis, Tenn. NovaLign recently received its first 510(k) clearance from the FDA to market its new Intramedullary Fixation System, a new system of implants and instruments for the treatment of long bone fractures, including the humerus, tibia and femur.

Amwell is a telehealth platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The company offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers telehealth solutions for over 240 health systems comprised of 2,000 hospitals and 55 health plan partners with over 36,000 employers, reaching over 150 million lives. Amwell was founded in 2006 and is headquartered in Boston, Massachusetts.

Third Wave Technologies, Inc. engages in the development and marketing of molecular diagnostic products for various DNA and RNA analysis applications. It provides physicians and researchers with molecular solutions for the analysis and treatment of disease. The company offers products based proprietary Invader chemistry, a technology used in women's health, infectious disease, genetics and pharmacogenetics, and oncology segments. Third Wave principally offers inVitro diagnostic devices and analyte specific reagents. The company's analyte specific reagents allow laboratories to create assays to perform hepatitis C virus genotyping, inherited disorders testing, and a host of other mutations associated with genetic predispositions and other diseases. Third Wave also develops various DNA and RNA analysis products for the research and agricultural biotechnology markets. Its customers include clinical laboratories, pharmaceutical and biotechnology companies, academic research centers, and health care providers. Third Wave sells its products through a combination of direct sales personnel who focuses primarily on the clinical market, as well as through collaborative relationships in the United States and Europe. The company was founded in 1993 and is headquartered in Madison, Wisconsin. As of July 23, 2008, Third Wave Technologies Inc. operates as a subsidiary of Hologic Inc.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Urgent Team Holdings, Inc. operates urgent care centers that provide urgent and primary health care services. It offers services for patients in the areas of sprains, strains, and broken bones; muscular pain and injuries; eye irritation and eye injuries; cuts and scrapes; bites, stings, and allergic reactions; burns and infections; diarrhea, nausea, and vomiting; flu, colds, and viral illnesses; pneumonia and bronchitis; and asthma attacks. The company also offers preventative screenings/wellness services, including flu shots, physicals, immunization and vaccinations, EKGs, and osteoporosis screening, as well as blood glucose, blood pressure, and cholesterol checks; radiology, lab work and diagnostic testing, and drug and alcohol screening services; and services for employers.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system to defeat cancer. It offers XTX201, a solution that induces immune activity in tumors and demonstrates improved antitumor activity. The company’s tumor-selective immunotherapies are based on its technology, which maximizes the potency of immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. Xilio Therapeutics, Inc. was formerly known as Akrevia Therapeutics, Inc. and changed its name to Xilio Therapeutics, Inc. in March 2020. The company was incorporated in 2015 and is based in Waltham, Massachusetts.

Cognis is a worldwide supplier of specialty chemicals and nutritional ingredients, with a particular focus on the areas of wellness and sustainability. The company employs about 5,600 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and provides value adding solutions and products based on renewable raw materials. The company serves the food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, as well as agriculture and mining.

CardioKinetix, Inc. develops transcatheter implants. Its portfolio includes Parachute, a ventricular partitioning device that intends to treat heart failure resulting from a heart attack in patients by improving the overall cardiac function. The company’s Parachute is deployed within the left ventricle for patients who have developed ischemic left sided heart failure following a heart attack. It serves customers primarily in the United States, France, Germany, Latvia, Portugal, Serbia, Slovenia, the Netherlands, and the United Kingdom. The company was incorporated in 2002 and is headquartered in Menlo Park, California.

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

According to American Heart Association statistics, 20,000-40,000 patients in the United States would benefit from a heart transplant. The MicroMed DeBakey VAD®, jointly developed with Dr. Michael DeBakey, Dr. George Noon and the National Aeronautics and Space Administration (NASA), has the potential to keep many of these people alive until a donor heart becomes available. Weighing less than four ounces, the device is silent and is approximately 1/10 the size of other pulsatile products on the market. The MicroMed DeBakey VAD® is designed to be a lower-cost, less invasive alternative to the commercially available, larger ventricular assist devices (VADs).

AeroCare is a durable medical equipment (DME) company that provides respiratory therapy services, medical equipment, and equipment cleaning supplies. AeroCare provides equipment and services for home oxygen, nebulized respiratory medications, and sleep therapy. AeroCare's patients are most often diagnosed with diseases that make breathing very difficult such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Obstructive Sleep Apnea (OSA).

Link Medicine was launched in 2005 by three men with a shared vision: Peter Lansbury, Link's founder and a leading neuroscience researcher from Harvard University, Ed Rudman, a private investor and philanthropist who less than a decade before had been diagnosed with Parkinson's disease, and Adam Rosenberg, an entrepreneur who years before saw his grandfather struggle with Parkinson's disease and his grandmother battle Alzheimer's disease.

QurAlis Corporation discovers and develops therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases. The company’s pipeline includes treatments for subtypes of ALS, such as a drug to restore a dysfunctional cellular waste clearance system that poisons neurons; a therapy to treat overactive neurons and prevents resulting cell death; and an approach to remove toxic proteins. The company was incorporated in 2016 and is based in Cambridge, Massachusetts. QurAlis Corporation operates as a subsidiary of Q-State Biosciences, Inc.

Synarc is the world's largest Central Radiology service dedicated exclusively to clinical trials. Synarc's in-house radiologists and scientists are leading authorities in the use of medical imaging and molecular markers in drug development, and have pioneered many methods currently used in clinical trials. With six offices around the world, Synarc currently manages over 150 clinical trials, involving more than 50,000 patients at 1,500 sites worldwide. Our services integrate all aspects of the design and execution of imaging and molecular markers in clinical trials across a spectrum of diseases in Oncology, Arthritis, Osteoporosis, Neurology, and Orthopaedics.

Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The company was co-founded by Mark Gelfand and Howard R. Levin, M.D., the proven team of innovators and entrepreneurs behind Coridea. The company is backed by top-tier venture investors Third Rock Ventures and SV Life Sciences.

Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease. Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy.

Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It provides Wireless Cardiac Stimulation of the Left Ventricle System, an endocardial pacing system for cardiac resynchronization therapy, which is a treatment for heart failure that uses an implantable pacemaker to improve the pumping efficiency of the heart by synchronizing the left and right ventricles. The company was founded in 2003 and is headquartered in Sunnyvale, California.

Enara Bio Limited is a biotechnology company. The company develops vaccines and immunotherapies for treating and preventing cancer. It offers dark antigens and T-cells. The company also develops technology platform to explore dark antigen repertoire and to identify and assess its tumor specificity and immunogenic potential to combat cancers. The company was formerly known as ErVaxx Limited and changed its name to Enara Bio Limited in June 2020. Enara Bio Limited was founded in 2016 and is headquartered in Oxford, United Kingdom.

Socios Mayores en Salud, Inc., doing business as American Health Medicare, provides health plans.

Thesan Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to the development of novel therapeutics for disorders of the skin. Until recently, there has been comparatively limited innovation in the field of dermatology, where many companies have focused on the reformulation of existing drugs often resulting in marginal patient benefit. In contrast, Thesan is focused on the discovery and development of New Chemical Entities that have the potential to provide significantly improved treatment options to patients.

Rheostat Therapeutics, Inc., a biotech company, engages in the discovery of treatments for neurodegeneration, cognition, and rare diseases. The company was incorporated in 2018 and is based in Cambridge, Massachusetts.

Homecare Homebase, based in Dallas, Texas, is a leading healthcare software company serving the technology needs of the fast growing homecare and hospice industry. Twice named Best In KLAS for Homecare by KLAS in 2010 and 2011 “Best in KLAS Awards: Software & Services” report, Homecare Homebase offers a comprehensive integrated cloud-based software solution to improve the clinical, operational and financial success of homecare and hospice agencies. Homecare Homebase enables real-time, wireless information exchange and communication between office staff, field staff and physicians; automates workflow processes; enables accurate billing through numerous integrated checks and balances; and, provides powerful management reporting via a back-office data analysis tool that ties together all agency operational information. Founded by industry veterans in 1999, every aspect of the Homecare Homebase system was developed to be user-friendly, flexible and customizable to specific agency needs.

Clarify Medical, Inc. develops home therapy solutions for chronic skin treatments. It offers The Clarify mobile ultra violet B treatment system, an investigational device for use in treating plaque psoriasis, eczema, and vitiligo; and Home Light Therapy System, a home phototherapy system for the treatment of psoriasis, vitiligo, and eczema. Clarify Medical, Inc. was formerly known as Skylit Medical, Inc. and changed its name to Clarify Medical, Inc. in September 2016. The company was incorporated in 2014 and is based in San Diego, California.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).

Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Leica Microsystems GmbH designs and produces precision optics systems for the analysis of microstructures. The company offers microscopy, confocal laser scanning microscopy, imaging systems, specimen preparation, and medical equipment for microscopic imaging, measurement, and analysis. Its products include light microscopes, stereomicroscopes, surgical microscopes, confocal microscopes, macroscopes, histology systems, materials sectioning systems, imaging systems, camera systems, and electron microscopy sample preparation systems. The company offers its products for applications in education, clinical, life science research, industrials and materials, special systems, forensic, digital cameras, quality control, routine manuals, and research manuals, as well as in dental, ENT, gynaecologic, neurosurgery, ophthalmic, orthopedic, plastic/reconstructive, and veterinary surgeries. It also provides system solutions in the areas of life science, including biotechnology and medicine, as well as the science of raw materials and industrial quality assurance. The company was founded in 1997 and is headquartered in Wetzlar, Germany. As of July 1, 2005, Leica Microsystems GmbH operates as a subsidiary of Danaher Corp.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Urgent Team Holdings, Inc. operates urgent care centers that provide urgent and primary health care services. It offers services for patients in the areas of sprains, strains, and broken bones; muscular pain and injuries; eye irritation and eye injuries; cuts and scrapes; bites, stings, and allergic reactions; burns and infections; diarrhea, nausea, and vomiting; flu, colds, and viral illnesses; pneumonia and bronchitis; and asthma attacks. The company also offers preventative screenings/wellness services, including flu shots, physicals, immunization and vaccinations, EKGs, and osteoporosis screening, as well as blood glucose, blood pressure, and cholesterol checks; radiology, lab work and diagnostic testing, and drug and alcohol screening services; and services for employers.

EBT Medical is a clinical-stage startup developing disruptive neuromodulation therapies for pelvic health disorders. EBT was founded based on scientific discoveries made at the University of Toronto and successfully incubated by their startup program, which has helped create over 500 companies in the last 10 years.

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

AXYS Pharmaceuticals, Inc. is engaged in discovery, design, and development of therapeutic small molecules that addressed significant markets with major unmet medical needs. It collaborates with large pharmaceutical companies in discovering therapeutics for chronic diseases. In addition, it also discovers and develops therapeutics for the treatment of various types of cancer and other specialty therapeutic opportunities. AXYS Pharmaceuticals, Inc. was formerly known as Arris Pharmaceuticals, Incorporated. The company is based in South San Francisco, California. As of November 16, 2001, AXYS Pharmaceuticals, Inc. operates as a subsidiary of Celera Corporation.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba’s technology is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, asthma/COPD and acute lung injury.

GelTex Pharmaceuticals develops and markets non-absorbed polymer drugs that bind and eliminate targeted substances within the gastrointestinal tract. It also develops small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators. Its focus areas include hyperphosphatemia, hypercholesterolemia, cancer, iron overload, and infectious diseases. GelTex Pharmaceutics is based in Waltham Massachusetts.

AavantiBio, Inc. engages in developing gene transfer therapy and gene editing technologies to improve the lives of people living with fatal diseases. It focuses on Friedreich’s Ataxia (FA), a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company was incorporated in 2019 and is based in Gainesville, Florida.

Acufocus, Inc., a medical device company, engages in the research, development, and marketing of solutions for the treatment of presbyopia. The company develops KAMRA, a corner inlay for the treatment of near vision loss that allows patients to see near and intermediate objects clearly; and AcuTarget, a system that is used to guide surgeons on surgical placement of the KAMRA. Its products are used in eye care centers in the United States, Asia, and Europe. Acufocus, Inc. was founded in 2001 and is based in Irvine, California.

Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the development of novel anti-infective medicines. The Affinium FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors for a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway.

Creating novel bispecific antibodies that activate the immune system to fight cancer

NKT Therapeutics, Inc., a biotechnology company, engages in developing therapeutics based on immune cells called natural killer T cells (NKT) It focuses to develop a pipeline of NKT based therapeutics to treat sickle cell disease, autoimmune and inflammatory diseases, and cancer. The company was incorporated in 2008 and is based in Waltham, Massachusetts.

Perfuze develops technology to treat acute ischemic stroke. The company was founded in 2018 and is based in Galway, Ireland.

Eyebiotech is a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases.

Artios Pharma Limited, a biotechnology company, focuses on developing cancer treatments that target DNA damage response (DDR) pathways to selectively kill cancer cells. Its product pipeline includes DNA polymerase theta (Polθ), which is involved in multiple processes associated with DNA repair; an in-licensed program that targets a protein that has been identified as a novel DNA damage response target; and a novel cancer treatment targeting DNA nucleases involved in the DDR. The company was incorporated in 2015 and is headquartered in Cambridge, United Kingdom.

Founded in 2013, Maestro Health is an American employee benefits company that provides integrated one-stop shopping experiences, along with private-labeled exchange solutions. It also offers employee health and benefits management solutions for brokers, small employers, and Fortune 1000 organizations. It combines private exchange, benefits administration, enrollment, self-insurance, healthcare savings account administration, and components on its integrated mobile and web platform, maestroEDGE. The company owns and operates a proprietary private exchange and medical TPA, which allows the streamlined integration of care management to drive down costs for employers.

Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (“GSK”). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels.

Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.

Karus Therapeutics Limited is a biopharmaceutical company that develops medicines for cancer. Its portfolio includes orally-active small molecule drugs, including KA2237, a dual-selective inhibitor of PI3K isoforms, such as p110ß and p110d for treating hematological and solid tumors; and KA2507 (HDAC6) for PD-L1 expressing tumors. The company was incorporated in 2005 and is based in Oxfordshire, United Kingdom.

Bardy Diagnostics, Inc. develops and manufactures cardiac monitoring devices. It offers Carnation Ambulatory Monitor (CAM), a cardiac patch monitor to capture low amplitude and frequency electrical signals that form the P-wave. The company also provides BDxCONNECT, a patient management system to the CAM patch, which offers a single system for creating, accessing, and managing patient CAM reports; and CAM reports that enables users to identify arrhythmia to aid clinical decision-making. Bardy Diagnostics, Inc. was incorporated in 2013 and is headquartered in Seattle, Washington. It has additional offices in Houston, Texas and New Providence, New Jersey.

Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.

CHF Solutions manufactures innovative medical devices for cardiac care. Its mission is to provide medical practitioners with practical solutions that enable the treatment of patients with unmet clinical needs. CHF Solutions was founded in 1998 and is based in Brooklyn Park, Minnesota.

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Aptiv Solutions, Inc. operates as a clinical research organization that offers clinical trial services. The company also provides adaptive trial design, simulation, and execution; early phase development consulting; pre clinical development; and drug development services. The company also provides regulatory compliance consulting services, which include strategy development, agency advisory, legal representation, and submission management services. It also offers therapeutic services in the areas of oncology, cardiology, dermatology, respiratory, and orphan diseases. Further, the company develops AptivAdvantage, an integrated technology platform for the implementation and execution of adaptive clinical trials. Aptiv Solutions, Inc. was formerly known as Averion International Corp. and changed its name to Aptiv Solutions, Inc. in February 2011. The company was founded in 1983 and is based in Reston, Virginia with an office in Durham, North Carolina.

Altura Medical is an emerging medical device company based in Menlo Park, CA that is developing a next generation endograft technology to treat abdominal aortic aneurysms (“AAA”) and other related disease states. Development of the company’s highly differentiated technology is led by an experienced management team and supported by a prestigious syndicate of venture capital investors.

TransEnterix, Inc. operates as a medical-device company which develops minimally invasive laparoscopic surgery platform. Its platform allows a surgeon to remove a patient's gall bladder and perform other abdominal surgeries without a scar. The company was founded in 2006 and is based in Durham, North Carolina. In 2013, SafeStitch Medical completed a reverse merger with TransEnterix, Inc., and the combined company was renamed TransEnterix.

Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK, with an innovative approach to allergy. The company is developing a novel class of oral anti-allergic medicines, called CRTH2 antagonists, to treat atopic dermatitis, asthma and allergic rhinitis. Its lead candidate is currently being studied in a Phase 2 clinical trial for moderate to severe atopic dermatitis in several leading European dermatology centres.

Catabasis Pharmaceuticals is a biopharmaceutical company located in Cambridge, Massachusetts focused on the discovery and development of innovative drugs to treat inflammatory conditions. Their platform technology enables the discovery and development of small molecules that simultaneously and specifically target pathways in the inflammatory response. The Catabasis platform will lead to the development of a novel mechanism of action therapies to safely and effectively treat inflammatory diseases.

AeroCare is a durable medical equipment (DME) company that provides respiratory therapy services, medical equipment, and equipment cleaning supplies. AeroCare provides equipment and services for home oxygen, nebulized respiratory medications, and sleep therapy. AeroCare's patients are most often diagnosed with diseases that make breathing very difficult such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Obstructive Sleep Apnea (OSA).

CRO is supporting the development and manufacturer.

As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Sirona is the worldwide dental technology leader and delivers outstanding customer focused solutions for dental practices, clinics and laboratories.

VHsquared Ltd. develops oral biologics for immuno-inflammatory targets in the gastro intestinal tract. The company identifies, screens, selects, and engineers Vorabodies, a transformational therapy for the treatment of inflammatory bowel disease. It uses its Vorabody platform to generate potent protease resistant domain antibodies for oral administration. The company was incorporated in 2010 and is based in Cambridge, United Kingdom.

Ophthotech Corporation, a biopharmaceutical company, develops various therapeutics to treat diseases of the eye. It is developing Fovista, which has completed Phase IIb clinical trials for use in combination with anti-VEGF drugs for the treatment of wet age-related macular degeneration (wet AMD); and ARC1905, a potent and selective inhibitor of complement factor C5 that has completed Phase I/IIa clinical trials to treat wet AMD. The company was founded in 2007 and is headquartered in New York, New York.

AqueSys, Inc., an ophthalmic company, focuses on innovating and commercializing implantable devices that improves the treatment of glaucoma. It offers XEN, a gel stent that creates a diffuse outflow of aqueous from the anterior chamber into the non-dissected tissue of the subconjunctival space. The company’s XEN gel stent creates a new pathway to allow the excess fluid in eyes to flow out, and lowers the eye pressure. AqueSys, Inc. was incorporated in 2005 and is based in Aliso Viejo, California. As of October 16, 2015, AqueSys, Inc. operates as a subsidiary of Allergan plc.

EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It provides Wireless Cardiac Stimulation of the Left Ventricle System, an endocardial pacing system for cardiac resynchronization therapy, which is a treatment for heart failure that uses an implantable pacemaker to improve the pumping efficiency of the heart by synchronizing the left and right ventricles. The company was founded in 2003 and is headquartered in Sunnyvale, California.

JET HEALTH provides skilled nursing care, hospice support, physical, speech and occupational therapy, rehabilitative care, medical social services, personal care, and companion services. Jet Health leverages local brands and operating expertise while sharing best practices across its companies and centralizing traditional back-office functions. The company believes that its four cornerstones: superior service, clinical excellence, compliant business practices, and an employee-centric environment provide a solid foundation upon which to build a successful company in the home health marketplace. Founded in April 2016, Jet Health is building a national platform through organic growth, strategic acquisitions, and de novo build-outs in target markets. These markets are typically mid-sized cities that have underserved and growing Medicare populations.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Entellus Medical, Inc., doing business as Stryker ENT, designs, develops, and commercializes products for minimally invasive treatment of chronic sinusitis, eustachian tube dysfunction, and nasal airway obstruction. The company offers XprESS ENT, a dilation system that delivers a combination of control and versatility for sinus and eustachian tube balloon dilation; XprESS LoProfile, a customizable fit patients anatomy for sinus and eustachian tube balloon dilation procedures; LATERA absorbable nasal implant, an implant that supports upper and lower lateral cartilage by anchoring maxilla to provide cantilever support; HD wireless camera; sterilization tray; and endoscopic imaging solutions. It also provides surgical instruments and tools, reinforced anesthesia needle, seekers and freers, sickle knife, forceps, suction and irrigation systems, shaver systems, sterilization tray, suction pumps, image-guided instruments, and nasal packing instruments. Entellus Medical, Inc. was founded in 2006 and is headquartered in Plymouth, Minnesota. As of February 28, 2018, Entellus Medical, Inc. operates as a subsidiary of Stryker Corporation.

Evidation Health is a provider of a health data analytics platform designed to collect and analyze continuous behavior data and healthcare information so as to create better health outcomes. Its platform turns raw, high-frequency everyday behavior data from sensors, devices, speech, video, and other sources into new knowledge about health and disease, that enable individuals and innovative companies to understand and influence the everyday behaviors. It was founded in 2012 and is headquartered in San Mateo, California.

AlloCure, Inc., a biotechnology company, develops cell therapies for the treatment of kidney diseases. The company develops AC607, a biologic therapy under development for acute kidney injury with applications in other grievous illnesses. AlloCure, Inc. was formerly known as Nephrogen, LLC and changed its name to AlloCure, Inc. in 2008. The company was founded in 2006 and is based in Burlington, Massachusetts with an additional location in Salt Lake City, Utah.

Ophthotech Corporation, a biopharmaceutical company, develops various therapeutics to treat diseases of the eye. It is developing Fovista, which has completed Phase IIb clinical trials for use in combination with anti-VEGF drugs for the treatment of wet age-related macular degeneration (wet AMD); and ARC1905, a potent and selective inhibitor of complement factor C5 that has completed Phase I/IIa clinical trials to treat wet AMD. The company was founded in 2007 and is headquartered in New York, New York.

Centauri Health Solutions is a technology-centric company specializing in hosted software solutions, data-driven services, and data management designed specifically for risk adjustment and quality based revenue programs.

Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.